Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Iltefat Hamzavi

Procedural Dermatology Canton, MI Medical Doctor

NPI 1538117866 CMS profile 251447

285 N Lilley Rd, Canton, MI 48187

Open in the dashboard

General payments

$458,162

452 records reported · program years 2019–2025

Research payments

$40,650

Paid to them · 28 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$869,990 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Iltefat Hamzavi of Canton, MI is reported in the CMS Open Payments database as having received $458,162 across 452 general payments and $40,650 in research payments paid to them. Separately, studies naming them as principal investigator received $869,990 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Procedural Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $150,010 96
2025 Research $17,770 14
2024 General $80,628 72
2024 Research $5,740 5
2023 General $98,353 96
2023 Research $5,400 1
2022 General $48,799 91
2022 Research $10,140 5
2021 General $69,923 53
2021 Research $1,600 3
2020 General $3,814 7
2019 General $6,635 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Iltefat Hamzavi
  • Procedural Dermatology median
  • Middle half of Procedural Dermatology
  • National median

In program year 2025, general payments to Iltefat Hamzavi were reported at $150,010. Among 381 Procedural Dermatology profiles paid that year, the median was $592 and the middle half received between $144 and $1,778.

Show as a table
Year Iltefat Hamzavi Procedural Dermatology median Middle half National median
2019 $6,635 $454 $152–$1,260 $163
2020 $3,814 $243 $90–$835 $114
2021 $69,923 $337 $102–$1,128 $132
2022 $48,799 $443 $119–$1,654 $149
2023 $98,353 $583 $137–$1,838 $160
2024 $80,628 $611 $132–$1,835 $164
2025 $150,010 $592 $144–$1,778 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $182,095 72 payments
  2. Incyte Corporation $121,477 106 payments
  3. AbbVie, Inc. $50,569 62 payments
  4. UCB, Inc. $48,188 42 payments
  5. Merck Sharp & Dohme Corporation $14,890 14 payments
  6. Ucb SA $9,635 2 payments
  7. Novartis Pharmaceuticals Corporation $9,180 33 payments
  8. Avita Medical Americas, LLC $8,522 6 payments
  9. Galderma Laboratories, L.P. $4,312 6 payments
  10. Janssen Global Services, LLC $2,910 3 payments
  11. Other $6,383 106 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $361,321 102 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $66,080 34 payments
  3. Travel and Lodging $21,665 64 payments
  4. Food and Beverage $7,798 248 payments
  5. Honoraria $1,116 2 payments
  6. Education $182 2 payments
Products named General payments · program years 2019–2025
  1. LITFULO $97,078 26 payments
  2. OPZELURA $29,323 31 payments
  3. Bimzelx $28,266 30 payments
  4. RINVOQ $21,672 21 payments
  5. CIBINQO $7,633 6 payments
  6. RECELL Dermatology $5,522 5 payments
  7. COSENTYX $3,784 14 payments
  8. Recell Wound Care $3,000 1 payment
  9. AKLIEF $1,585 2 payments
  10. HUMIRA $839 13 payments
  11. Other $4,286 202 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $35,250 27 payments
  2. Novartis Pharma AG $5,400 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

317

Median for Dermatology: 534

Drug cost

$198,748

Median for Dermatology: $67,151

Branded share of claims

21.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira Adalimumab Brand 14 $99,343
Dupixent Pen Dupilumab Brand 14 $54,483
Opzelura Ruxolitinib Phosphate Brand 18 $35,115
Tacrolimus Generic 25 $3,359
Fluorouracil Generic 26 $1,643
Tranexamic Acid Generic 12 $1,370
Ketoconazole Generic 39 $886
Clobetasol Propionate Generic 24 $559
Fluocinolone Acetonide Generic 13 $439
Fluocinonide Generic 17 $396

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$145,529

Of which drugs: $847

Medicare patients

797

Average age 73

Services billed

3,823

379 women, 418 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 44%
Diabetes 26%
Ischemic heart disease 26%
Chronic kidney disease 21%
Depression 19%
Cancer 15%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 38 73 $48

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LITFULO
  • PFIZER INC. $29,692
$29,692 — —
OPZELURA
  • Incyte Corporation $15,551
$15,551 18 —
Bimzelx
  • UCB, Inc. $14,898
$14,898 — —
CIBINQO
  • PFIZER INC. $1,306
$1,306 — —
RINVOQ
  • AbbVie, Inc. $1,200
$1,200 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

480 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Procedural Dermatology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record